11 stories mentioning BMY
Every FINWIRES story that references BMY, newest first.
Bristol-Myers Squibb (BMY) has an average rating of overweight and mean price target of $63.26, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $56.75, Change: $-0.16, Percent Change: -0.28%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $60 from $73, 9.7x our 2027 EPS estimate, a discount to BMY's 10-year historical forward P/E average. We keep our 2026 EPS estimate at $6.30 and our 2027 EPS forecast at $6.18. While we think the company has been successfully navigating a period of important transition with solid performance from its growth portfolio, we think declines in the legacy products could put pressure on top-line growth in the next quarters. While key drug Eliquis (anticoagulant) performed better than anticipated in Q1, demonstrating resilience with revenues of $4.1B, we think competition will get fiercer with generic entry as the European patent expired on May 19. We think going forward, the key focus for BMY will be pipeline progress and the evolution of sales from new drugs. However, we see top-line revenue declines in the next two years while leverage remains more elevated versus peers due to recent acquisitions. Shares of BMY rose by nearly 19% since we gave our Buy rating on September 30.
The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning trading Monday, as Wall Street monitored oil prices and US Treasury yields amid the ongoing conflict in the Middle East.In company news, NextEra Energy (NEE) and Dominion Energy (D) said Monday they have entered into a definitive agreement to combine in an all-stock deal. Under the terms of the transaction, Dominion shareholders will receive a fixed exchange ratio of 0.8138 shares of NextEra for each Dominion share they own at the close of the deal, which is expected in the next 12 to 18 months. NextEra shareholders will own about 74.5% of the combined company, while Dominion shareholders will own the remaining 25.5%. NextEra shares were down 5.5% around midday, while Dominion shares were up 9.6%.The US Supreme Court on Monday denied writ of certiorari petitions by six big pharmaceutical companies seeking to challenge the legality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act of 2022. AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol-Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court. Shares of AstraZeneca, Novartis, Johnson & Johnson and Bristol-Myers were up 1.1%, 0.8%, 0.4% and 0.5%, respectively, while Novo Nordisk was down 1%.Berkshire Hathaway (BRK.A, BRK.B) disclosed Friday in a regulatory filing that it sold all of its stake in UnitedHealth Group (UNH). Separately, a New York state court judge on Monday prohibited prosecutors from using some evidence found in the backpack of Luigi Mangione, who is standing trial for the murder of UnitedHealth Group's UnitedHealthcare CEO Brian Thompson, CNBC reported. UnitedHealth shares were down 1.5%, while Berkshire's class A and class B shares were up 0.2% and 0.1%, respectively.Citigroup (C) and BlackRock's (BLK) HPS Investment Partners are launching a 15 billion euro ($17.48 billion) private capital program to expand access to private financing for corporate and sponsor-owned borrowers in the Europe, the Middle East and Africa region, the companies said Monday. Citigroup shares were down 0.2%, while BlackRock shares were up 0.5%.Price: $88.24, Change: $-5.13, Percent Change: -5.49%
The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022.AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.The companies did not immediately respond to requests for comment from.Price: $183.25, Change: $+1.67, Percent Change: +0.92%
Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $73 from $69, 11.7x our 2027 EPS estimate, a discount to BMY's 10-year historical forward P/E average. We lift our 2026 EPS estimate to $6.30 from $6.22 and maintain our 2027 EPS forecast at $6.18. BMY announced Q1 revenues of $11.5B, a 1% Y/Y increase, and non-GAAP EPS of $1.58, above expectations. The company's growth portfolio, which includes key products such as Reblozyl, Breyanzi, Opdualag, Qvantig, and Cobenfy, and is a key area of focus, saw a 9% Y/Y increase in sales, driven by strong demand for BMY's newer medicines. The quarter was also marked by significant progress in the company's pipeline, with positive data for its CELMoD program and advancements in several late-stage assets. We think the company is successfully navigating a period of important transition, with strong performance from its growth portfolio offsetting declines in legacy products, as we anticipate a series of crucial clinical trial readouts later in the year.
Bristol-Myers Squibb (BMY) Q1 results were solid but driven largely by legacy products rather than growth drivers, while the stock is expected to remain range-bound in the near term until more concrete data emerges in H2, RBC Capital Markets said.The brokerage said in a Thursday note that the about 5% rally in the stock reflected increasing pipeline confidence following the Q1 call, rather than the quarterly results themselves.RBC said it was encouraged by the growing attention on the often overlooked CELMoD franchise, which offers several potential opportunities that could support upside.The firm reiterated a sector perform rating with a price target of $60, saying further upside will depend on successful pipeline execution.Price: $58.65, Change: $-1.95, Percent Change: -3.21%
Bristol-Myers Squibb Company (BMY) has an average rating of overweight and mean price target of $63.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $58.90, Change: $-1.69, Percent Change: -2.79%
Bristol-Myers Squibb Company (BMY) has an average rating of overweight and mean price target of $63.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $58.90, Change: $-1.69, Percent Change: -2.79%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BMY delivered solid Q1 2026 results with revenues of $11.5B (+3% Y/Y), $580M above the consensus. Meanwhile, non-GAAP EPS of $1.58 declined 12% Y/Y but beat the consensus by $0.16. Growth Portfolio demonstrated exceptional strength with 12% Y/Y expansion to $6.2B, now representing the majority of total sales versus the Legacy Portfolio at $5.3B (-6% Y/Y). We think the company's diversification strategy is showing clear progress, with standout performances from Camzyos ($314M, +97% Y/Y), Breyanzi ($411M, +56% Y/Y), and continued Eliquis resilience ($4.1B, +16% Y/Y). Management reaffirmed 2026 revenue guidance of $46.0B-$47.5B and non-GAAP EPS guidance of $6.05-$6.35, with performance trending toward upper end of range. We believe the Growth Portfolio momentum positions BMY well for future growth despite Legacy Portfolio headwinds from generic competition, particularly after Revlimid's sharp decline to $349M (-63% Y/Y).
Bristol-Myers Squibb's (BMY) Q1 results are expected to come in line with consensus, but weaker oncology sales and one-off factors are likely to give way to volatility, RBC Capital Markets said Friday in a note.The investment firm said the quarter will be difficult to model due to volatility from destocking patterns, tough year-over-year comparisons, policy impacts and generic phasing dynamics.RBC said it estimates the company to report Q1 revenue of $10.75 billion and earnings of $1.42 per share. Analysts polled by FactSet expect $1.42 in non-GAAP EPS, $1.17 in GAAP EPS and $10.87 billion in revenue.Investor focus during the quarterly call will be on the company's upcoming trial results, particularly late-stage data for drug candidates milvexian and cobenfy, which are key to determining when Bristol-Myers returns to growth.Bristol-Myers will report Q1 results on April 30.RBC has a sector perform rating and price target of $60 on the stock.Price: $58.62, Change: $-0.85, Percent Change: -1.44%